Home › Research › Biomarkers
The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease
Shasha Hu, Haizhou Yu, Jianjun Gao. Drug discoveries & therapeutics, 2025-06-28
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
As the most prevalent form of dementia, Alzheimer's disease (AD) represents a major public health challenge. Early diagnosis is crucial to delaying disease progression, and yet the gold standard for detection of biomarkers - cerebral positron emission tomography (PET) imaging and cerebrospinal fluid biomarker analysis - is constrained by invasiveness, high costs, and limited accessibility. On May 16, 2025, the FDA granted its first clearance to the Lumipulse G blood test, which utilizes the plasma pTau217/Aβ1-42 ratio, for the diagnosis of amyloid plaques in symptomatic patients age 55 or older. In clinical validation, concordance rates with amyloid PET brain scans/the results of cerebrospinal fluid biomarker detection were 91.7% (positive) and 97.3% (negative). Similar blood-based assays have previously been approved in Japan (HISCL™ Aβ42/40), the United Kingdom (PrecivityAD2™), and China. While concerns regarding false-positive/false-negative rates necessitate continued attention and their role as adjunctive diagnostic tools requires integration with comprehensive clinical assessment and other tests, the rapid development and regulatory clearance of these blood-based biomarker assays undeniably offer promising prospects for transforming the diagnostic and therapeutic paradigm for AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hu, S., Yu, H., & Gao, J. (2025). The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease. Drug discoveries & therapeutics. https://doi.org/10.5582/ddt.2025.01055
Vancouver
Hu S, Yu H, Gao J. The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease. Drug discoveries & therapeutics. 2025. doi:10.5582/ddt.2025.01055. PMID: 40582836.
BibTeX
@article{hu2025-40582836,
author = {Hu, Shasha and Yu, Haizhou and Gao, Jianjun},
title = {{The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease}},
journal = {Drug discoveries \& therapeutics},
year = {2025},
doi = {10.5582/ddt.2025.01055},
pmid = {40582836},
url = {https://doi.org/10.5582/ddt.2025.01055}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In clinical validation, concordance rates with amyloid PET brain scans/the results of cerebrospinal fluid biomarker detection were 91.7% (positive) and 97.3% (negative).
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Effect size91.7%; 97.3%
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 26 of the 56 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Drug discoveries & therapeutics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40582836) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 26 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 26 of the 56 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.